Drug Profile
Exemestane - Pfizer
Alternative Names: Aromasil; Aromasin; Aromasine; FCE 24304; Nikidess; PNU 155971Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Emory University; German Breast Group; Pfizer
- Class Androstadienes; Antineoplastics; Small molecules
- Mechanism of Action Aromatase inhibitors; Estrogen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
Most Recent Events
- 07 Dec 2021 Efficacy data from the phase III SOFT and TEXT trials presented at the 44th Annual San Antonio Breast Cancer Symposium (SABCS-2021)
- 12 Jun 2018 German Breast Group and Pfizer completes a phase III trial in Breast cancer (Male breast cancer, Combination therapy, Adjuvant therapy, Neoadjuvant therapy) in Germany (PO) (NCT01638247) (EudraCT2009-015122-11)
- 22 Jan 2018 Pfizer completes a phase III trial in Breast cancer (Prevention) in USA, Canada, Puerto Rico and France (PO) (NCT00083174)